Literature DB >> 21455239

The resurgence of covalent drugs.

Juswinder Singh1, Russell C Petter, Thomas A Baillie, Adrian Whitty.   

Abstract

Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.

Mesh:

Substances:

Year:  2011        PMID: 21455239     DOI: 10.1038/nrd3410

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  68 in total

Review 1.  Binding energy, specificity, and enzymic catalysis: the circe effect.

Authors:  W P Jencks
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1975

2.  Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer.

Authors:  Paraskevi Vogiatzi; Pier Paolo Claudio
Journal:  Expert Rev Anticancer Ther       Date:  2010-07       Impact factor: 4.512

Review 3.  Covalent modifiers: an orthogonal approach to drug design.

Authors:  Michele H Potashman; Mark E Duggan
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

4.  Kinetic basis for selective inhibition of cyclo-oxygenases.

Authors:  J K Gierse; C M Koboldt; M C Walker; K Seibert; P C Isakson
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

5.  Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Authors:  Harold J Burstein; Yan Sun; Luc Y Dirix; Zefei Jiang; Robert Paridaens; Antoinette R Tan; Ahmad Awada; Anantbhushan Ranade; Shunchang Jiao; Gary Schwartz; Richat Abbas; Christine Powell; Kathleen Turnbull; Jennifer Vermette; Charles Zacharchuk; Rajendra Badwe
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans.

Authors:  Donglu Zhang; Rajesh Krishna; Lifei Wang; Jianing Zeng; James Mitroka; Renke Dai; Narayanan Narasimhan; Richard A Reeves; Nuggehally R Srinivas; Lewis J Klunk
Journal:  Drug Metab Dispos       Date:  2004-10-22       Impact factor: 3.922

7.  Targeted covalent drugs of the kinase family.

Authors:  Juswinder Singh; Russell C Petter; Arthur F Kluge
Journal:  Curr Opin Chem Biol       Date:  2010-07-06       Impact factor: 8.822

Review 8.  Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.

Authors:  John Cl Erve
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

9.  Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).

Authors:  Allan Wissner; Elsebe Overbeek; Marvin F Reich; M Brawner Floyd; Bernard D Johnson; Nellie Mamuya; Edward C Rosfjord; Carolyn Discafani; Rachel Davis; Xiaoqing Shi; Sridhar K Rabindran; Brian C Gruber; Fei Ye; William A Hallett; Ramaswamy Nilakantan; Ru Shen; Yu-Fen Wang; Lee M Greenberger; Hwei-Ru Tsou
Journal:  J Med Chem       Date:  2003-01-02       Impact factor: 7.446

10.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Authors:  Todd A Carter; Lisa M Wodicka; Neil P Shah; Anne Marie Velasco; Miles A Fabian; Daniel K Treiber; Zdravko V Milanov; Corey E Atteridge; William H Biggs; Philip T Edeen; Mark Floyd; Julia M Ford; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Shamal A Mehta; Hitesh K Patel; William Pao; Charles L Sawyers; Harold Varmus; Patrick P Zarrinkar; David J Lockhart
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-26       Impact factor: 11.205

View more
  431 in total

1.  On the mechanism of dimethylarginine dimethylaminohydrolase inactivation by 4-halopyridines.

Authors:  Corey M Johnson; Arthur F Monzingo; Zhihong Ke; Dae-Wi Yoon; Thomas W Linsky; Hua Guo; Jon D Robertus; Walter Fast
Journal:  J Am Chem Soc       Date:  2011-06-23       Impact factor: 15.419

Review 2.  Targeting protein kinases with selective and semipromiscuous covalent inhibitors.

Authors:  Rand M Miller; Jack Taunton
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

3.  An allenic Pauson-Khand approach to 6,12-guaianolides.

Authors:  Francois Grillet; Chaofeng Huang; Kay M Brummond
Journal:  Org Lett       Date:  2011-11-09       Impact factor: 6.005

Review 4.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

5.  The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule.

Authors:  Benedict C S Cross; Peter J Bond; Pawel G Sadowski; Babal Kant Jha; Jaroslav Zak; Jonathan M Goodman; Robert H Silverman; Thomas A Neubert; Ian R Baxendale; David Ron; Heather P Harding
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 6.  The influence of the 'organizational factor' on compound quality in drug discovery.

Authors:  Paul D Leeson; Stephen A St-Gallay
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

7.  Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas.

Authors:  Giulia Palermo; Davide Branduardi; Matteo Masetti; Alessio Lodola; Marco Mor; Daniele Piomelli; Andrea Cavalli; Marco De Vivo
Journal:  J Med Chem       Date:  2011-09-08       Impact factor: 7.446

8.  ALARM NMR for HTS triage and chemical probe validation.

Authors:  Jayme L Dahlin; Matthew Cuellar; Gurpreet Singh; Kathryn M Nelson; Jessica Strasser; Todd Rappe; Youlin Xia; Gianluigi Veglia; Michael A Walters
Journal:  Curr Protoc Chem Biol       Date:  2018-04-09

9.  Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction.

Authors:  Rosa Cardoso; Robert Love; Carol L Nilsson; Simon Bergqvist; Dawn Nowlin; Jiangli Yan; Kevin K-C Liu; Jing Zhu; Ping Chen; Ya-Li Deng; H Jane Dyson; Michael J Greig; Alexei Brooun
Journal:  Protein Sci       Date:  2012-11-09       Impact factor: 6.725

10.  Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay.

Authors:  Andrew J Storaska; Jian P Mei; Meng Wu; Min Li; Susan M Wade; Levi L Blazer; Benita Sjögren; Corey R Hopkins; Craig W Lindsley; Zhihong Lin; Joseph J Babcock; Owen B McManus; Richard R Neubig
Journal:  Cell Signal       Date:  2013-09-14       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.